Primary outcome
TEAEs
The primary end point, incidence of TEAEs (time frame, up to 52 weeks of treatment and 4 weeks of follow-up) not being different between treatment arms was met. In total, 86.1–88.4% of resmetirom-treated patients and 81.8% of placebo-treated patients reported a TEAE during the trial (Table Safety summary (safety population)GI, gastrointestinal.